ClearNote Health’s Avantect Multi-Cancer Detection Test selected for National Cancer Institute’s Vanguard Study
ClearNote Health announced that its Avantect Multi-Cancer Detection Test was selected for the Vanguard Study funded by the National Cancer Institute (NCI), part of the National Institutes of Health.
The Avantect Multi-Cancer Detection Test was one of two tests selected after a thorough evaluation of emerging multi-cancer detection technologies. The Vanguard Study aims to address the feasibility of using targeted multi-cancer detection tests in randomized controlled trials (RCTs) designed to assess the clinical benefit of cancer detection, possibly in the early stages, through noninvasive blood tests.
For a more thorough evaluation of early cancer detection with emerging technologies, NCI has launched the Cancer Screening Research Network (CSRN). Its first effort will be to conduct the Vanguard Study, a pilot study of targeted multi-cancer detection tests. The CSRN involves nine geographically diverse clinical trial hubs that will enroll up to 24,000 total participants for the Vanguard Study to assess the feasibility of using multi-cancer detection tests in future RCTs.
The Avantect Multi-Cancer Detection Test is a simple blood test to screen for cancer in asymptomatic, generally healthy persons. It was designed to detect some of the deadliest types of cancer by profiling both the epigenomic biomarker 5-hydroxymethylcytosine (5hmC) and genomic features in cell-free DNA. Unlike conventional methods, ClearNote’s 5hmC-based approach provides a specific signal of early cancer development by measuring changes in active biology. This enables detection of the presence of cancer along with its likely tissue of tumor origin.
